Moderna announces advances across mrna pipeline and provides business update

Covid-19 vaccine sales for 2022 approximately $18.4 billion (unaudited) reiterating 2023 expected minimum covid-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023 company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing r&d investment to an expected $4.5 billion for 2023 pivotal phase 3 rsv study of mrna-1345 in older adults ( ≥ 60 yrs.) has now accrued the cases required to complete our first interim efficacy analysis moderna and merck announced mrna-4157/v940, in combination with keytruda, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients.
MRNA Ratings Summary
MRNA Quant Ranking